COMPASS Pathways (CMPS) stock price is $11.97, up 0.59% on the day, as of Oct 21, 2026. It has a market cap of $1.62Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.62 Bn
P/E-4.10
Div. Yield0.00
Total Debt (Qtr)50.73 Mn
Add ratio to table…
About
Compass Pathways plc is a biotechnology company dedicated to accelerating patient access to evidence based innovation in mental health. The company is developing its investigational COMP360 psilocybin treatment, a proprietary formulation of pharmaceutical grade polymorphic crystalline psilocybin designed for stability and purity. Its initial focus is on treatment resistant depression, with additional programs underway for post traumatic stress disorder and other mental…
Compass Pathways plc is a biotechnology company dedicated to accelerating patient access to evidence based innovation in mental health. The company is developing its investigational COMP360 psilocybin treatment, a proprietary formulation of pharmaceutical grade polymorphic crystalline psilocybin designed for stability and purity. Its initial focus is on treatment resistant depression, with additional programs underway for post traumatic stress disorder and other mental health conditions. Compass Pathways plc conducts clinical trials across North America and Europe and has reported positive results from Phase 2b and Phase 3 studies of COMP360 in treatment resistant depression.
As a clinical stage company, Compass Pathways plc has not yet generated revenue from product sales because its lead product remains investigational and has not received regulatory approval. The firm finances its operations through equity offerings and collaboration agreements, directing funds toward research development, clinical trials, and manufacturing arrangements with contract organizations. No product has been commercialized to date, so revenue from sales is currently zero.
Compass Pathways plc operates in the mental health therapeutics sector where it addresses conditions with high unmet need such as treatment resistant depression and post traumatic stress disorder. In the United States only two pharmacotherapies are approved for treatment resistant depression: Janssens Spravato (esketamine) and the olanzapine fluoxetine combination. The company faces competition from other biopharmaceutical firms developing alternative treatments including Supernus Pharmaceuticals, Neurocrine Biosciences, GH Research, Beckley PsyTECH and other psilocybin focused entities such as Helus Pharma formerly known as Cybin. Non profit organizations like the Usona Institute also pursue psychedelic research for similar indications. Competitive advantages for Compass Pathways plc stem from its proprietary COMP360 formulation, an extensive patent portfolio covering compositions and methods of treatment, the FDA Breakthrough Therapy designation received in 2018 for COMP360 in treatment resistant depression, and the positive outcomes from its Phase 3 pivotal trials which have demonstrated statistically significant and clinically meaningful improvements in depressive symptoms. The company retains global development and commercialization rights for COMP360 and plans an initial launch in the United States pending regulatory approval.
Compass Pathways plc’s current customers are primarily the clinical trial sites, health care providers and research collaborators involved in its studies. To prepare for potential commercialization, the company has entered into collaboration agreements with various U. S. health care delivery systems including Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Reliant Medical Group, Journey Clinical, Mindful Health Solutions, HealthPort and Radial Health. It also operates a Center of Excellence in partnership with King’s College London and the South London and Maudsley NHS Foundation Trust to support research and training initiatives. Additionally, Compass Pathways plc works with academic institutions on investigator initiated studies, working with partners such as Imperial College London, King’s College London, the University of California San Diego School of Medicine, the Maryland Oncology Hematology group, the New York State Psychiatric Institute, Sheppard Pratt, the University of Copenhagen and the University of Zurich. These relationships help the company gather real world data, refine treatment delivery models and build expertise for future market entry.
Sector:HealthcareSector rationaleCompass Pathways is a biotechnology company developing COMP360, a pharmaceutical-grade psilocybin treatment for mental health conditions like treatment-resistant depression. Its core business activity involves conducting clinical trials and pursuing regulatory approval for a medical therapeutic, which falls directly under the Biotechnology and Pharmaceuticals industries within the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryCompass Pathways is a clinical-stage biotechnology company developing COMP360, a proprietary formulation of psilocybin for treatment-resistant depression and PTSD. Its business model focuses on biology-based drug discovery and development, currently financing operations through equity and collaboration agreements while conducting Phase 2b and Phase 3 clinical trials.Classified using BQ-MICSCIK: 0001816590
Bull & bear
Investment Thesis
▲ Bull case
The company has secured a rolling NDA submission for COMP360 with the FDA aligning on a process that allows modules to be filed over the coming months.This rolling approach reduces the burden of a single large filing and keeps the review timeline flexible.Additionally the award of a Commissioner’s National Priority Voucher creates a potential for an ultra accelerated review window of one to two months after the final module is submitted.Management noted that the voucher does not change the evidentiary bar but it does enable a more collaborative day to day interaction with the agency which could shave weeks off the traditional review period.Given that nearly ninety% of the US population resides in states that have pledged to reschedule the drug within thirty days of federal approval the path to patient access after clearance appears markedly shorter than historical averages for novel CNS agents.
Both pivotal Phase III studies in treatment resistant depression met their primary endpoint showing rapid onset and durable response.In the 005 trial a quarter of patients achieved a clinically meaningful response after a single dose while the 006 trial showed a forty% response after a second fixed dose.The durability data out to twenty six weeks is expected to reinforce the notion that the effect persists beyond the acute phase.With over one thousand patients exposed across the late stage program the safety database is robust and shows a generally well tolerated profile.These results differentiate COMP360 from the current standard of care Spravato which requires frequent dosing and has a lower overall response rate in the real world.
Management reiterated that the company aims to be launch ready by the end of the current year.To support this goal the commercial organization has been rapidly expanded with a leadership team that has collectively launched more than fifty products in various therapeutic areas.This depth of experience in go to market strategy pricing and payer engagement reduces execution risk typical of early stage biotechs.Parallel to hiring the company has secured Category III CPT3 codes that will allow providers to bill hourly for the monitoring required during a psychedelic session.The expectation is that utilization data will drive a conversion to Category I status which would lock in reimbursement rates and further encourage provider adoption.
The interventional psychiatry centers that currently administer Spravato already possess the rooms staffing and workflows needed for COMP360.Because the drug and the monitoring model share similar requirements no new capital investment is necessary for these sites to begin offering the treatment.Representatives from these centers have expressed enthusiasm for a therapy that can be given in one or two sessions rather than the frequent dosing schedule of Spravato.This existing network covers roughly seventy five hundred sites which together serve a large fraction of the treatment resistant depression population.The ability to leverage this ready made distribution channel accelerates the time to revenue and lowers the customer acquisition cost.
Early conversations with payers have highlighted the economic burden of treatment resistant depression where patients incur sixty two% higher mental health care costs and forty one% higher work related costs compared to non resistant depression.COMP360’s profile of rapid and durable relief offers the potential to reduce overall utilization of inpatient visits emergency room use and repeated medication trials.The company is preparing to present health economic models that demonstrate possible cost offsets for insurers.Should these models resonate payers may be inclined to grant favorable formulary placement and to support buy and bill billing arrangements.A positive payer stance would not only improve access but also could support a premium pricing strategy relative to older generics.
The company has secured a rolling NDA submission for COMP360 with the FDA aligning on a process that allows modules to be filed over the coming months.This rolling approach reduces the burden of a single large filing and keeps the review timeline flexible.Additionally the award of a Commissioner’s National Priority Voucher creates a potential for an ultra accelerated review window of one to two months after the final module is submitted.Management noted that the voucher does not change the evidentiary bar but it does enable a more collaborative day to day interaction with the agency which could shave weeks off the traditional review period.Given that nearly ninety% of the US population resides in states that have pledged to reschedule the drug within thirty days of federal approval the path to patient access after clearance appears markedly shorter than historical averages for novel CNS agents.
Both pivotal Phase III studies in treatment resistant depression met their primary endpoint showing rapid onset and durable response.In the 005 trial a quarter of patients achieved a clinically meaningful response after a single dose while the 006 trial showed a forty% response after a second fixed dose.The durability data out to twenty six weeks is expected to reinforce the notion that the effect persists beyond the acute phase.With over one thousand patients exposed across the late stage program the safety database is robust and shows a generally well tolerated profile.These results differentiate COMP360 from the current standard of care Spravato which requires frequent dosing and has a lower overall response rate in the real world.
Management reiterated that the company aims to be launch ready by the end of the current year.To support this goal the commercial organization has been rapidly expanded with a leadership team that has collectively launched more than fifty products in various therapeutic areas.This depth of experience in go to market strategy pricing and payer engagement reduces execution risk typical of early stage biotechs.Parallel to hiring the company has secured Category III CPT3 codes that will allow providers to bill hourly for the monitoring required during a psychedelic session.The expectation is that utilization data will drive a conversion to Category I status which would lock in reimbursement rates and further encourage provider adoption.
The interventional psychiatry centers that currently administer Spravato already possess the rooms staffing and workflows needed for COMP360.Because the drug and the monitoring model share similar requirements no new capital investment is necessary for these sites to begin offering the treatment.Representatives from these centers have expressed enthusiasm for a therapy that can be given in one or two sessions rather than the frequent dosing schedule of Spravato.This existing network covers roughly seventy five hundred sites which together serve a large fraction of the treatment resistant depression population.The ability to leverage this ready made distribution channel accelerates the time to revenue and lowers the customer acquisition cost.
Early conversations with payers have highlighted the economic burden of treatment resistant depression where patients incur sixty two% higher mental health care costs and forty one% higher work related costs compared to non resistant depression.COMP360’s profile of rapid and durable relief offers the potential to reduce overall utilization of inpatient visits emergency room use and repeated medication trials.The company is preparing to present health economic models that demonstrate possible cost offsets for insurers.Should these models resonate payers may be inclined to grant favorable formulary placement and to support buy and bill billing arrangements.A positive payer stance would not only improve access but also could support a premium pricing strategy relative to older generics.
Although the Commissioner’s National Priority Voucher suggests a possible one to two month review after final NDA submission the FDA has not guaranteed that an advisory committee will be waived.The agency retains the discretion to convene an AdCom which could add several weeks or months to the timeline.Management acknowledged that they do not yet have an indication of whether an AdCom will be required and said they would be prepared if one is called.Any delay in the review process would postpone launch beyond the targeted end of year window and could erode the cash runway advantage.Investors should note that the voucher does not alter the evidentiary standard so a negative or mixed readout from the pending twenty six week data could still lead to a complete response letter.
The rolling submission is contingent on receiving the Part B twenty six week results from the 006 study which are expected in early Q3.Should that data show a diminution of durability or an unexpected safety signal the filing would be incomplete and the NDA could be delayed or rejected.The company has not disclosed what specific thresholds they view as success for the long term readout leaving some ambiguity about what the market should expect.This reliance on a single data set creates a binary risk factor where the outcome of one trial heavily influences the entire valuation.Historically psychiatric programs have experienced setbacks at the long term safety stage making this a material concern.
While nearly ninety% of the US population lives in states that have pledged to reschedule COMP360 within thirty days of federal approval the actual execution depends on DEA scheduling and individual state legislative processes.Some states may require additional rulemaking or governor sign off which could extend the timeline beyond the stated thirty day window.The DEA’s own review may not align with the accelerated pace envisioned by the executive order and could take longer than the current statutory ninety days post FDA approval.A patchwork of implementation dates would create confusion for providers and could limit the effective addressable market at launch.Any significant delay in rescheduling would directly impede patient access and could force the company to rely on a slower specialty pharmacy model rather than the preferred buy and bill pathway.
The Category III CPT3 codes currently in place are temporary tracking mechanisms that require sufficient utilization data before the American Medical Association can recommend a permanent Category I valuation.If the AMA’s Relative Value Update Committee delays its review or assigns a low relative value unit the hourly reimbursement rate may be insufficient to cover provider costs.Payers are not obligated to accept Category III codes for reimbursement and may continue to apply prior authorization hurdles or low fee schedules.Without a robust Category I rate the financial incentive for clinics to adopt COMP360 could be muted especially when compared to existing therapies with established payment structures.The company’s ability to negotiate favorable payer contracts hinges on demonstrating clear health economic benefits which may take time to materialize.
Interventional psychiatry centers are accustomed to the rapid turnover model of Spravato where a room can be used for multiple patients in a single day.COMP360 sessions are expected to last approximately six hours which limits the number of treatments that can be performed daily and may reduce per room revenue potential.Providers may be reluctant to sacrifice throughput for a novel therapy unless they are convinced of superior clinical outcomes or enhanced reimbursement.Additionally the REMS requirements though expected to resemble those of Spravato still impose training documentation and monitoring obligations that could be perceived as burdensome.Slow uptake at the site level would translate into lower than anticipated prescription volumes and could affect the company’s ability to reach blockbuster sales.
Although the Commissioner’s National Priority Voucher suggests a possible one to two month review after final NDA submission the FDA has not guaranteed that an advisory committee will be waived.The agency retains the discretion to convene an AdCom which could add several weeks or months to the timeline.Management acknowledged that they do not yet have an indication of whether an AdCom will be required and said they would be prepared if one is called.Any delay in the review process would postpone launch beyond the targeted end of year window and could erode the cash runway advantage.Investors should note that the voucher does not alter the evidentiary standard so a negative or mixed readout from the pending twenty six week data could still lead to a complete response letter.
The rolling submission is contingent on receiving the Part B twenty six week results from the 006 study which are expected in early Q3.Should that data show a diminution of durability or an unexpected safety signal the filing would be incomplete and the NDA could be delayed or rejected.The company has not disclosed what specific thresholds they view as success for the long term readout leaving some ambiguity about what the market should expect.This reliance on a single data set creates a binary risk factor where the outcome of one trial heavily influences the entire valuation.Historically psychiatric programs have experienced setbacks at the long term safety stage making this a material concern.
While nearly ninety% of the US population lives in states that have pledged to reschedule COMP360 within thirty days of federal approval the actual execution depends on DEA scheduling and individual state legislative processes.Some states may require additional rulemaking or governor sign off which could extend the timeline beyond the stated thirty day window.The DEA’s own review may not align with the accelerated pace envisioned by the executive order and could take longer than the current statutory ninety days post FDA approval.A patchwork of implementation dates would create confusion for providers and could limit the effective addressable market at launch.Any significant delay in rescheduling would directly impede patient access and could force the company to rely on a slower specialty pharmacy model rather than the preferred buy and bill pathway.
The Category III CPT3 codes currently in place are temporary tracking mechanisms that require sufficient utilization data before the American Medical Association can recommend a permanent Category I valuation.If the AMA’s Relative Value Update Committee delays its review or assigns a low relative value unit the hourly reimbursement rate may be insufficient to cover provider costs.Payers are not obligated to accept Category III codes for reimbursement and may continue to apply prior authorization hurdles or low fee schedules.Without a robust Category I rate the financial incentive for clinics to adopt COMP360 could be muted especially when compared to existing therapies with established payment structures.The company’s ability to negotiate favorable payer contracts hinges on demonstrating clear health economic benefits which may take time to materialize.
Interventional psychiatry centers are accustomed to the rapid turnover model of Spravato where a room can be used for multiple patients in a single day.COMP360 sessions are expected to last approximately six hours which limits the number of treatments that can be performed daily and may reduce per room revenue potential.Providers may be reluctant to sacrifice throughput for a novel therapy unless they are convinced of superior clinical outcomes or enhanced reimbursement.Additionally the REMS requirements though expected to resemble those of Spravato still impose training documentation and monitoring obligations that could be perceived as burdensome.Slow uptake at the site level would translate into lower than anticipated prescription volumes and could affect the company’s ability to reach blockbuster sales.